The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine

Drug Metabolism and Disposition

Volumn 34, Issue 7, 2006, Pages 1116-1121

  Zhu, Hao Jie ^a   Wang, Jun Sheng ^b   DeVane, C Lindsay ^b   Williard, Robin L ^a   Donovan, Jennifer L ^b   Middaugh, Lawrence D ^b   Gibson, Brian B ^b   Patrick, Kennerly S ^a   Markowitz, John S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; GLYCOPROTEIN P; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; GENETIC VARIABILITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; INJECTIONS, INTRAPERITONEAL; MALE; METHYLPHENIDATE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; P-GLYCOPROTEIN; P-GLYCOPROTEINS;

EID: 33745271384     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009605     Document Type: Article

References (26)

1. al-Dirbashi O, Kuroda N, Menichini F, Noda S, Minemoto M, and Nakashima K (1998) Enantioselective high-performance liquid chromatography with fluorescence detection of methamphetamine and its metabolites in human urine. Analyst 123:2333-2337.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
3. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder Committee on Quality Improvement (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 108:1033-1044.
4. Balayssac D, Authier N, Cayre A, and Coudore F (2005) Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Let 156:319-329.
5. Biederman J and Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237-248.
6. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, upregulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
7. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The affect of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 33:165-174.
8. Faraone SV, Biederman J, and Roe C (2002) Comparative efficacy of Adderall and Methylphenidate in attention deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 22:468-473.
9. Fricker G and Miller DS (2004) Modulation of drug transporters at the blood-brain barrier. Pharmacology 70:169-176.
10. Greenhill LL, Halperin JM, and Abikoff H (1999) Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503-512.
11. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, et al. (2002) Practice parameters for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 41 (Suppl):26S-49S.
12. Ho RH and Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
13. Lee G and Bendayan R (2004) Functional expression and localization of p-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res (NY) 21:1313-1330.
14. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of p-glycoprotein. Adv Drug Deliv Rev 55:53-81.
15. Lin JH and Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98.
16. Löscher W and Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76.
17. Mann H, Ladenheim B, Hirata H, Moran TH, and Cadet JL (1997) Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdrla) knockout mice. Brain Res 769:340-346.
18. Patrick KS, González MA, Straughn AB, and Markowitz JS (2005) New methylphenidate formulations for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Drug Deliv 2:121-143.
19. Patrick KS and Markowitz JS (1997) Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol Clin Exp 12:527-546.
20. Pliszka SR, Brown R, Olvera RL, and Wynne SK (2000a) A double-blind, placebo controlled study of Adderall and methylphenidate in the treatment of attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619-626.
21. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners C, McCracken JT, Swanson JM, Hughes CW, Llana ME, et al. (2000b) The Texas children's medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention deficit/hyperactivity disorder. Part I. Attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:908-919.
22. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-194.
23. Schwab D, Fischer H, Tabatabaei A, Poli S, and Huwyler J (2003) Comparison of in vitro p-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46:1716-1725.
24. Wang J-S, Taylor R, Ruan Y, Donovan JL, Markowitz JS, and DeVane CL (2004a) Brain penetration of methadone R- and S-enantiomers is greatly increased by P-glycoprotein deficiency in the blood brain barrier of Abcb1a gene knockout mice. Psychopharmacology 173:132-138.
25. Wang J-S, Taylor R, Ruan Y, Donovan JL, Markowitz JS, and DeVane CL (2004b) Olanzapine penetration into brain is greater in transgenic Mdr1a P-glycoprotein deficient mice than FVB1 (wild type) animals. Neuropsychopharmacology 29:551-557.
26. Wilens TE and Biederman J (1992) The stimulants. Psychiatr Clin North Am 15:191-222.